艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2022.06.008

Abstract

Abstract: Objective This study was aimed at exploring the response to elbavir/glarevir antiviral therapy in patients with genotype 1b chronic hepatitis C (CHC). Methods 68 patients with genotype 1b CHC were recruited in our hospital and were divided into observation (n=34) and control (n=34) group, receiving elbavir/glarevir or ribavirin and peg-interferonα-2a combination therapy for 24 weeks. All the patients were followed-up for 24 weeks. Serum L-selectin, C-reactive protein (CRP), interleukin- 6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were detected by ELISA. Results The rapid virological response, early virological response, end-of-treatment response and sustained virological response in the observation group were 70.6%, 91.2%, 97.1% and 94.1%, all much higher than 41.2%, 55.9%, 64.7% and 55.9%(P＜0.05) in the control; at the end of 4, 12, 24 week treatment and 24 week follow-up, serum HCV RNA loads in the observation group were (1.5±0.9)lgIU/mL,(1.6±0.7)lgIU/mL, (1.2±0.6)lgIU/mL and (1.2±0.4)lgIU/mL, significantly lower than [(4.3±0.8)lgIU/mL, (4.7±0.9)lgIU/mL, (3.2±0.5)lgIU/mL and (3.2±0.5)lgIU/mL, respectively, P＜0.05] in the control; at the end of 24 week treatment, serum L-selectin, CRP, IL-6 and TNF-α levels in the observation group were (816.3±161.4)ng/mL, (13.7±1.9)ng/L, (84.4±18.8)pg/mL and (1.2±0.3) ng/mL, all significantly lower than [(1157.4±192.3)ng/mL, (16.3±2.0)ng/L, (115.9±20.5)pg/mL and (1.6±0.3)ng/mL, respectively, P＜0.05] in the control group; the white blood cell counts, platelet counts and hemoglobin level in the observation were (5.4±1.1)×10⁹/L, (101.3±17.3)×10⁹/L and (120.8±19.5)g/L, all significantly higher than [(3.2±0.8)×10⁹/L, (86.9±16.6)×10⁹/L and (101.6±16.2)g/L, respectively, P＜0.05] in the control. Conclusion The application of elbavir/glarevir in the treatment of CHC patients with genotype 1b infection is efficacious, with low untoward effects, which might be related to the low body response of inflammatory reactions.

Key words: Hepatitis C, Genotype 1b, Elbavir/glarevir, Virological response, Therapy

Xu Hailing, Qin Gang, Xue Hong, et al.. Response to elbavir/glarevir antiviral therapy in patients with genotype 1b chronic hepatitis C[J]. Journal of Practical Hepatology, 2022, 25(6): 788-791.

References

[1] Khalil FO,Alsebaey A, Kasemy ZA, et al. IL28B, TLR7 SNPs, and cytomegalovirus infection are risk factors for advanced liver disease in chronic hepatitis C patients. Expert Rev Anti Infect Ther,2022,20(1):121-129.
[2] Pott-Junior H, Luzeiro C, Senise JF,et al. Association of seasonality and serum albumin concentration with vitamin D deficiency in subjects with chronic hepatitis C infection living in a sunny country. Public Health Nutr,2020 ,23(7):1247-1253.
[3] Sohn W. Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma. Korean J Intern Med, 2021,36(2):286-287.
[4] Wijaya RS, Read SA, Selvamani SP,et al. Hepatitis C virus (HCV) eradication with interferon-free direct-acting antiviral-based therapy results in KLRG1⁺ HCV-specific memory natural killer cells. J Infect Dis, 2021,223(7):1183-1195.
[5] Cao X, Kang Q, DengJ,et al. Scavenger receptor class B type I is more conducive for genotype 1b hepatitis C virus internalization than low-density lipoprotein receptor. Acta Virol, 2021,65(3):279-287.
[6] Chiu SM, Tsai MC, LinCY,et al. Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A1-year follow-up study after treatment. PLoS One, 2020,15(4):1102.
[7] Pijnenburg DWM,Seyen M, Abbink EJ,et al. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection. J Antimicrob Chemother,2020,75(9):2661-2665.
[8] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2015年更新版.实用肝脏病杂志,2016,19(4):9-26.
[9] Shao C, Shao PP, ChenWT,et al. Direct-acting antiviral therapy improves the outcome of chronic hepatitis C/intermediate-stage B hepatocellular carcinoma patients. Anticancer Res,2021,41(4):2007-2016.
[10] Chayanupatkul M, Chittmittraprap S, Pratedrat P,et al. Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis. Antivir Ther, 2020,25(6):305-314.
[11] Kassas M, Alboraie M,Badry M,et al. Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study. Int J Infect Dis, 2020,96(6):367-370.
[12] Chen J, Li Y, LiG,et al. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. Ren Fail, 2020,42(1):377-380.
[13] Liu CH,Peng CY, Fang YJ,et al. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. Sci Rep,2020,10(1):9180.
[14] Stein K,Stoehr A, Klinker H,et al. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur J Gastroenterol Hepatol, 2022,34(1):76-83.
[15] Ji Q, Chu X, Zhou Y,et al. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. J Med Virol, 2022,94(2):675-682.
[16] Saafan AE, Abobaker A, Abbas MS,et al. Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4. J Infect Dev Ctries,2020,14(1):80-88.
[17] Khalil MA,Shousha HI,Nahaas SM,et al. Depression in patients with chronic hepatitis-C treated with direct-acting antivirals: A real-world prospective observational study. J Affect Disord, 2021,28(2):126-132.
[18] Fan C, Zhang X, ZhangP,et al. LPS stimulation during HCV infection induces MMP/TIMP1 imbalance in macrophages. J Med Microbiol, 2020,69(5):759-766.
[19] Abergel A, Asselah T, Mallat A,et al. Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int,2020,40(8):1853-1859.
[20] Asselah T, Pol S, Hezode C,et al. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. Liver Int,2020,40(5):1042-1051.

Response to elbavir/glarevir antiviral therapy in patients with genotype 1b chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[2]	Zhao Zide, Wu Lingjie, Zhang Haisheng, et al.. Could the supplement of human blood albumin product reduce the incidence of drug-induced liver injury in patients with pulmonary tuberculosis and hypoproteinemia? [J]. Journal of Practical Hepatology, 2022, 25(6): 792-795.
[3]	Sun Zheng, Wang Xiaoye, Yuan Jing, et al.. Short-term efficacy of dapagliflozin and liraglutide combination in treatment of patients with non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(6): 796-799.
[4]	Sun Ling, Hang Wei, Deng Guozhong. Short-term observation of metformin and pioglitazone combination in treatment of patients with non-alcoholic fatty liver diseases and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(6): 804-807.
[5]	He Jinfan, Yao Jia, Zhao Qiang, et al.. Vasovagal reaction in patients with liver failure during double plasma molecular adsorption system treatment [J]. Journal of Practical Hepatology, 2022, 25(6): 828-831.
[6]	Sun Jing, Zhang Weiwei, Ma Zhiyong, et al.. Prevention of varices re-bleeding in patients with liver cirrhosis undergoing transjugular intrahepatic portosystemie stent and gastric coronary vein embolization [J]. Journal of Practical Hepatology, 2022, 25(6): 853-856.
[7]	Mao Yueqin, Zhang Hongxia, Song Haiyan, et al.. Clinical efficacy of auxiliary DutanyuPixu Formulae therapy after TACE in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(6): 873-876.
[8]	Lan Sirong, Xu Jiwei, Zhang Yaoming, et al.. Guidance of real-time contrast-enhanced ultrasonography and 3D ultrasound fusion imaging for ablation area in patients with primary liver cancer during microwave ablation therapy [J]. Journal of Practical Hepatology, 2022, 25(6): 889-892.
[9]	Jiang Biao, Fu Tong, Wu Xudong. Short-term efficacy of high intensity focused ultrasound with auxiliary artificial plethorax in the treatment of children with unresectable hepatoblastoma [J]. Journal of Practical Hepatology, 2022, 25(6): 893-896.
[10]	Lu Xiaoming, Chen Xuemin. Efficacy and safety of PTBD and two-stage PTCSL in the treatment of patients with acute cholangitis with choledocholithiasis [J]. Journal of Practical Hepatology, 2022, 25(6): 901-904.
[11]	Nan Yuemin, Li Jiazheng. Liver cirrhosis and infections: the state of the disease [J]. Journal of Practical Hepatology, 2022, 25(5): 609-611.
[12]	Wang Yushan, Kong Yin, Liu Yuanyuan, et al.. Different switching therapy for chronic hepatitis B patients with low-level viraemia : a single-center retrospective study [J]. Journal of Practical Hepatology, 2022, 25(5): 633-636.
[13]	Xu Huan, Tan Junyuan, Huang He, et al.. Antiviral response and changes of TLR4 and B7-H1 in peripheral blood mononuclear cells by peginterferon α-2a and entecavir combination therapy in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(5): 637-640.
[14]	Wang Chunying, Qu Yaoning, Qiao Wei, et al.. Implication of serum HBV cccDNA and HBV pgRNA in patients with chronic hepatitis B receiving entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(5): 641-644.
[15]	Liu Yantong, Yao Yang, Lu Bo. Short-term efficacy of Heye Tiaozhi Shugan Decoction in dealing with patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 657-660.